The government needs to back local pharmaceutical manufacturing to reduce the risk of key shortages.
As research continues into appropriate therapies to treat covid-19, there are currently three experimental frontrunners: dexamethasone, remdesivir, and tocilizumab.
But even though these drugs are recommended for treating hospitalised covid patients in Australia, there’s significant concern that we could run out of supply.
With our medicine manufacturing capability severely lagging behind the rest of the world, Australia remains overexposed to global supply chains that can falter.
This episode we’re joined by Associate Professor Nial Wheate from the pharmacy school at the University of Sydney, to talk about the vulnerabilities in our medicines manufacturing system and the supply issues that are putting Australians at risk.
You can listen and subscribe to the show by searching for “The Tea Room Medical Republic” in your favourite podcast player.
